Positive Data for Inhaled Nicotine Replacement Therapy
A Phase 1 clinical trial of Qnovia's RespiRx handheld inhalable nicotine replacement therapy (NRT) revealed cigarette-comparable nicotine delivery with favorable safety profile.
A Phase 1 clinical trial of Qnovia's RespiRx handheld inhalable nicotine replacement therapy (NRT) revealed cigarette-comparable nicotine delivery with favorable safety profile.
A Phase 1 clinical trial of Qnovia’s RespiRx handheld inhalable nicotine replacement therapy (NRT) revealed cigarette-comparable nicotine delivery with favorable safety profile.
Read MoreThe phase 1 trial evaluates the nicotine inhaler as a smoking cessation therapy, aiming to improve nicotine delivery and support smokers in quitting.
Read More